Traditional randomized trials are often impractical for treatments in the rare and ultra rare disease space.
Dr. Patricia E. Greenstein
Advertisement
Articles by Dr. Patricia E. Greenstein
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
The Risks and Benefits of FDA Reviewing Real-Time Data
3
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
4
What Pharma Investors Should Expect in the Current Regulatory Environment
5